Abstract
Background Patients with cystic fibrosis (CF) are characterised by abnormalities of the intestinal tract relating to gut motility and physiological issues, with daily symptoms of disease including abdominal pain, flatulence, bloating, and constipation. With improvements in respiratory outcomes, a shift in disease manifestations has highlighted the prevalence of the gastrointestinal-related problems associated with CF, yet most therapies currently in clinical use for the gut symptoms of CF have been repurposed from other disease indications and have not been developed with a knowledge of the mechanisms underpinning gastrointestinal disease in CF. Increased attention towards the role of intestinal inflammation and microbial dysbiosis in the CF population warrants a comprehensive knowledge of these aspects alongside the increased luminal fat content, dysmotility, and small intestinal bacterial overgrowth (SIBO) resultant of the primary consequences of CFTR dysfunction (disrupted fluid secretion and pancreatic insufficiency), and how they contribute towards the intestinal complications of CF disease.
Methods and Study Design We will conduct a systematic review to comprehensively address our current understanding of the primary consequences of CFTR dysfunction, and their subsequent secondary effects that contribute towards the disruption of gut motility, health, and associated symptoms in the CF intestine. Databases searched will include PubMed, CINAHL, MEDLINE and the Cochrane library from 1939 until a specified date of last search, alongside clinical trial databases for ongoing studies. Search strategies will include various terminology that relates to the primary mechanistic defects of CF, postulated secondary effects of such defects, and symptoms experienced in patients. A full search strategy is outlined in appendix B. One reviewer will apply an inclusion criterion to obtained abstracts. Following agreement from a second reviewer, full-text articles will be sought, and data will be extracted from relevant articles. Disagreements will be resolved with a third reviewer. The quality of data will be assessed by the GRADE criteria. Data will be used to present a narrative, and where possible, quantitative synthesis.
Discussion This systematic review will discuss our current understanding of the underpinning mechanisms of the persisting abnormalities in gut health and motility within CF, addressing potential intricate relationships that further contribute to disease progression within the intestinal tract. Furthermore, we will identify current gaps in the literature to propose directions for future research. A comprehensive understanding of these aspects in relation to intestinal abnormalities will aid future clinical directions.
Competing Interest Statement
CN reports grants from Cystic Fibrosis Trust, grants from Cystic Fibrosis Foundation, grants and other from Vertex, outside the submitted work. GM reports an investigator initiated research grant from Vertex and research funding from Sanofi. ARS reports grants from Vertex, as well as speaker honoraria and expenses from Teva and Novartis and personal fees from Vertex, outside the submitted work. In addition, ARS has a patent issued Alkyl quinolones as biomarkers of Pseudomonas aeruginosa infection and uses thereof. The other authors have no conflicts to declare.
Funding Statement
A CF Trust Venture and Innovation Award (VIA 77) awarded to CJvdG funded this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
As this is a protocol for a systematic review, ethical approval is not required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Revisions include the additional omission of "case reports" within "Criteria for considering studies for this review". Additional revision includes clarity of CFTR genotyping within inclusion/exclusion criteria: Inclusion - Direct reporting of CFTR-dependent fluid secretion. Exclusion - Any study solely comparing CFTR genotype to the occurrence of intestinal abnormalities and symptoms in CF.
Data Availability
Due to the nature of this manuscript, supporting data is not available. A copy of the PRISMA-P guidelines is attached in the supplementary materials. This has been used to direct the structure of this systematic review protocol.
